Brace Pharma Capital

bracepharma.com

Brace Pharma Capital is a U.S. strategic investment company created by EMS S/A, the largest pharmaceutical company in Brazil. We invest in innovative therapies for diseases with high unmet medical needs and insufficient treatment options, including orphan diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ABBVIE SECURES POSITIVE CHMP OPINION FOR RISANKIZUMAB (SKYRIZI®) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE

AbbVie | September 19, 2022

news image

AbbVie announced the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. "We continue to raise the bar in researching treatments for immune-mediated gastroenterological condit...

Read More

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

news image

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More

BUSINESS INSIGHTS

ELEMENT MATERIALS TECHNOLOGY ANNOUNCES COMPLETION OF ITS ACQUISITION BY TEMASEK

Element and Temasek | July 08, 2022

news image

Element Materials Technology a global leader in testing, inspection, and certification services, has completed its acquisition by Temasek, a global investor headquartered in Singapore. Temasek has been a minority shareholder in Element since 2019. Temasek has acquired Element from Bridgepoint, whose successful ownership has been an important part of a more than ten-fold increase in Element’s turnover over the past decade. The acquisition, which was subject to regulatory approvals, was prev...

Read More

BUSINESS INSIGHTS

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

news image

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More
news image

BUSINESS INSIGHTS

ABBVIE SECURES POSITIVE CHMP OPINION FOR RISANKIZUMAB (SKYRIZI®) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE

AbbVie | September 19, 2022

AbbVie announced the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. "We continue to raise the bar in researching treatments for immune-mediated gastroenterological condit...

Read More
news image

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More
news image

BUSINESS INSIGHTS

ELEMENT MATERIALS TECHNOLOGY ANNOUNCES COMPLETION OF ITS ACQUISITION BY TEMASEK

Element and Temasek | July 08, 2022

Element Materials Technology a global leader in testing, inspection, and certification services, has completed its acquisition by Temasek, a global investor headquartered in Singapore. Temasek has been a minority shareholder in Element since 2019. Temasek has acquired Element from Bridgepoint, whose successful ownership has been an important part of a more than ten-fold increase in Element’s turnover over the past decade. The acquisition, which was subject to regulatory approvals, was prev...

Read More
news image

BUSINESS INSIGHTS

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More